Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $244.81M. The enterprise value is ―.
Market Cap$244.81M
Enterprise Value―
Share Statistics
Monte Rosa Therapeutics has 61,509,823 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,509,823
Owned by Insiders22.89%
Owned by Institutions39.96%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -55.19%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-55.19%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee0.00
Profits Per Employee-953.18K
Employee Count142
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is -2.15. Monte Rosa Therapeutics’s PEG ratio is -0.23.
PE Ratio-2.15
PS Ratio0.00
PB Ratio2.41
Price to Fair Value1.62
Price to FCF-5.90
Price to Operating Cash Flow-8.63
PEG Ratio-0.23
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 0.00 and earned -135.35M in profits. Earnings per share was -2.63.
Revenue0.00
Gross Profit-6.22M
Operating Income-143.31M
Pretax Income-135.01M
Net Income-135.35M
EBITDA-137.09M
Earnings Per Share (EPS)-2.63
Cash Flow
In the last 12 months, operating cash flow was -57.29M and capital expenditures -5.49M, giving a free cash flow of -62.79M billion.
Operating Cash Flow-57.29M
Free Cash Flow-62.79M
Free Cash Flow per Share-1.02
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.07
52-Week Price Change-16.97%
50-Day Moving Average4.95
200-Day Moving Average6.13
Relative Strength Index (RSI)41.07
Average Volume (3m)655.68K
Important Dates
Monte Rosa Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of 5.07, with Debt / Equity ratio of 21.27%
Current Ratio5.07
Quick Ratio5.07
Debt to Market Cap0.00
Net Debt to EBITDA0.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid 338.00K in taxes.
Income Tax338.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is -1.52, with an EV/FCF ratio of -3.32.
EV to Sales0.00
EV to EBITDA-1.52
EV to Free Cash Flow-3.32
EV to Operating Cash Flow-4.76
Balance Sheet
Monte Rosa Therapeutics has $242.19M in cash and marketable securities with $43.70M in debt, giving a net cash position of -$198.49M billion.
Cash & Marketable Securities$242.19M
Total Debt$43.70M
Net Cash-$198.49M
Net Cash Per Share-$3.23
Tangible Book Value Per Share$3.49
Margins
Gross margin is 75.54%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin75.54%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $14.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.75
Price Target Upside270.60% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast61.09%